Fennec Pharmaceuticals Inc. (FENC)
NASDAQ: FENCHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
FENC stock chart
Technical analysisKey statistics
All statistics- Market cap
- $462.14M
- P/E (TTM)
- 436.33
- Forward P/E
- 12.47
- EPS (TTM)
- $0.03
- Dividend yield
- None
- 52-week range
- 5.65 – 13.85
- Day range
- 12.64 – 13.55
- Volume / Avg
- 398.14K / 220.87K
- Beta
- —
- Shares outstanding
- 35.31M
52-week range
FENC stock today
Shares of Fennec Pharmaceuticals (FENC) finished lower on Nov 20 at $13.09, a drop of 2.68% or $0.36 per share, versus the S&P 500's 3.70% decline. At this level, FENC sits near the top of its 52-week range of $5.65 to $13.85: 5.5% below the high, set on Nov 18, 2026 and 131.7% above the low. FENC is up 70.0% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 66.1%.
Fennec Pharmaceuticals trades at 436.3x its trailing twelve-month earnings per share of $0.03. Its forward P/E of 12.5x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.
Summary generated from market data by MetaCap's automated system. Methodology
About Fennec Pharmaceuticals
Company profileFennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. Jeffrey S. Hackman
- Headquarters
- Research Triangle Park, NC
- Employees
- 35
- Website
- fennecpharma.com
Financial highlights
Full financialsIn fiscal 2025, Fennec Pharmaceuticals generated $44.6 million in revenue, down 6.1% from fiscal 2024, the first decline in the 28 years shown. Fennec Pharmaceuticals reported a net loss of $9.7 million, compared with a loss of $436,000 a year earlier. Operating margin was -14.1%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $44.64M | $47.54M | $21.25M | $1.53M | — |
| Growth | -6.09% | +123.69% | +1284.50% | — | — |
| Net income | $-9.74M | $-436.00K | $-16.05M | $-23.71M | $-17.35M |
| EPS (diluted) | $-0.34 | $-0.02 | $-0.60 | $-0.90 | $-0.67 |
Analyst forecast
ForecastConsensus (5 analysts)
strong_buy
Avg. price target
$17.60+34.45%
- Strong buy 1
- Buy 4
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $0.12 vs $0.09
- Surprise
- +33.33%
FENC news
All FENC news- Fennec Pharma (FENC) Q3 2026 Earnings Call TranscriptNasdaq
- Fennec Pharmaceuticals Swings To Profit In Q3 On Surging PEDMARK Sales; Stock UpNasdaqFENC, BF.A
- Fennec Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswire
- Fennec Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 12, 2026GlobeNewswire
Fennec Pharmaceuticals peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| RGNXREGENXBIO Inc. | 7.16 | -0.28% | $473.44M | vs FENC |
| SANASana Biotechnology Inc. | 1.59 | -8.62% | $476.42M | vs FENC |
| DNAGinkgo Bioworks Holdings Inc. Class A | 7.46 | -9.02% | $483.54M | vs FENC |
| VALNValneva SE ADR | 5.16 | -3.82% | $490.86M | vs FENC |
| IRLAIRulya Therapeutics Inc. | 39.88 | -0.15% | $432.36M | vs FENC |
| PROKProKidney Corp. Class A | 1.04 | -1.89% | $415.21M | vs FENC |
| ETRAElectra Therapeutics Inc. | 8.11 | -9.28% | $509.85M | vs FENC |
| TECXTectonic Therapeutic Inc. | 20.73 | -1.47% | $405.26M | vs FENC |
Indexes, lists and sector
Fennec Pharmaceuticals stock FAQ
What is Fennec Pharmaceuticals's stock price today?
FENC last traded at $13.09 as of Nov 20, 4:00 PM EST, down 2.68% on the day. Prices are delayed at least 15 minutes.
What is FENC's P/E ratio?
FENC trades at a trailing P/E ratio of 436.33 and a forward P/E of 12.47.
Who is Fennec Pharmaceuticals's CEO?
Mr. Jeffrey S. Hackman is the chief executive officer of Fennec Pharmaceuticals Inc., which has about 35 employees.
What is the FENC 52-week high?
The 52-week high for FENC is $13.85 and the 52-week low is $5.65. The stock is currently 5.5% below its high.